Quantifying Myofascial Dysfunction in Post-Stroke Pain

Myofascial Dysfunction Clinical Trial

— Myofascial  

Official title:

Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05762679
• Other study ID #: IRB00354876
• Secondary ID: 1R61AT012279-01
• Status: Completed
• Start date: February 28, 2023
• Est. completion date: May 24, 2024

Study information

• Verified date: June 2024
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to quantify the extent of GlycosAminoGlycan/Hyaluronic Acid (GAG/HA) accumulation using T1rho (T1ρ) MRI in the paretic versus non-paretic shoulder rotator muscles, and correlate the T1ρ Magnetic Resonance Imaging (MRI) measurements with US echo texture measurements to develop a clinic-friendly tool to infer the extent of HA accumulation; and to distinguish between latent versus active Post Stroke Shoulder Pain (PSSP) using ultrasound (US) shear strain mapping of the same muscles on the paretic side compared with the non-paretic side.

Description:

Shoulder pain is extremely common after stroke and occurs in 30-70% of patients. Chronic post stroke shoulder pain (PSSP) contributes to depression, interferes with motor recovery, and decreases quality of life. Although PSSP is thought to be caused by damage to the myofascial tissues around the shoulder joint, the pathophysiology of myofascial dysfunction and pain in PSSP has not been elucidated, leading to missed opportunities for early diagnosis, and variable success with pain management. The accumulation of HA in muscle and its fascia can cause myofascial dysfunction. HA is a GAG and a chief constituent of the extracellular matrix of muscle. In physiologic quantities, it functions as a lubricant and a viscoelastic shock absorber, enabling force transmission during muscle contraction and stretch. Reduced joint mobility and spasticity can result in focal accumulation and alteration of HA in muscle, leading to the development of taut bands, dysfunctional gliding of deep fascia and muscle layers, Reduced Range of Motion (ROM), and pain. Muscle HA concentrations can be imaged using T1ρ MRI, and myofascial dysfunction can be assessed using echo texture analysis and shear strain mapping on quantitative US, which may serve as useful biomarkers to elucidate the pathophysiology of myofascial dysfunction in PSSP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: May 24, 2024
• Est. primary completion date: May 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older

• Hemiparesis from Ischemic or Hemorrhagic Stroke

• 4-120 months post-stroke with Hemiparesis since the incidence and intensity of PSSP

• Show a difference of more than 10 degrees of passive ER-ROM between non-paretic and paretic shoulders with or without pain

• Able to provide informed consent and comply with testing protocols

Exclusion Criteria:

• Received treatment for spasticity with Botulinum Toxin or Intrathecal Baclofen within the past three months

• Have another neurologic condition that may affect motor response (e.g. Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS))

• Have a contraindication to MRI (claustrophobia, magnetic pacemakers and clips)

• Have non-musculoskeletal PSSP such as only central pain or Chronic Regional Pain Syndrome (CRPS)

• Have a complicated medical condition, or significant injury to either upper limb.

Related Conditions & MeSH terms

• Myofascial Dysfunction

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland

Sponsors (4)

Lead Sponsor	Collaborator
Johns Hopkins University	George Mason University, National Center for Complementary and Integrative Health (NCCIH), New York University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To quantify the extent of HA accumulation in shoulder muscles using quantitative MRI and US.	Comparison of T1rho (T1?) MRI of pectoralis major and infraspinatus muscles in paretic and non-paretic shoulders	Baseline
Primary	To distinguish between latent versus active PSSP using US shear strain mapping of the same muscles on the paretic side compared with the non-paretic side.	Comparison of peak lateral shear strain of pectoralis major and infraspinatus muscles in paretic latent vs active PSSP compared to non-paretic shoulders	Baseline